<DOC>
	<DOC>NCT03078322</DOC>
	<brief_summary>The study will evaluate the safety and efficacy of AV-101.</brief_summary>
	<brief_title>AV-101 as Adjunct Antidepressant Therapy in Patients With Major Depression</brief_title>
	<detailed_description />
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder, Major</mesh_term>
	<mesh_term>Antidepressive Agents</mesh_term>
	<criteria>Diagnosed with MDD, single or recurrent, and currently experiencing a MDE of at least 8 weeks in duration. Has a history of inadequate response to at least 1 approved antidepressant including at least 1 and no more than 3 during the current depressive episode. Meet the threshold on the total HAMD17 score of &gt; 20 If female, a status of nonchildbearing potential or use of an acceptable form of birth control. Body mass index between 18 to 40 kg/m2. Other criteria may apply Current diagnosis of Axis I disorders other than persistent depressive disorder, agoraphobia, generalized anxiety disorder, social anxiety disorder, panic disorder, posttraumatic stress disorder, attention deficit disorder, complicated grief, binge eating disorder, obsessive compulsive disorder of mild severity, other specified anxiety disorder, or specific phobia unless one of these is clinically unstable. (Note: MDD must be the primary diagnosis). History of bipolar disorder, schizophrenia or schizoaffective disorders, or any history of psychotic symptoms in the current or previous depressive episodes. History of anorexia nervosa, bulimia nervosa, or other specified feeding or eating disorder, within 5 years of screening. Women who are pregnant or breastfeeding or a positive pregnancy test at screening or baseline. Currently taking a prohibited adjunct therapy. Such drugs must be washed out for at least 4 weeks prior to baseline. Current diagnosis of moderate or severe substance use (including alcohol) disorder (abuse or dependence, as defined by DSM5), with the exception of nicotine dependence, at screening or within 6 months prior to screening. In the opinion of the investigator, the subject has a significant risk for suicidal behavior Has received electroconvulsive therapy, or had repetitive transcranial magnetic stimulation in the current episode. Has received vagus nerve stimulation at any time prior to screening. Any current or past history of any physical condition, which in the investigator's opinion might put the subject at risk or interfere with study results interpretation.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>